COST-MINIMIZATION ANALYSIS OF ETRAVIRINE AND RALTEGRAVIR USED IN THERAPY FOR HIV INFECTION
- Authors: BELOUSOV Y.B1, AFANASYEVA E.V2, BELOUSOV D.Y.2, BEKETOV A.S2
-
Affiliations:
- N.I. Pirogov Russian National Research Medical University
- OOO Center of Pharmacoeconomic Studies
- Issue: No 1 (2012)
- Pages: 60-64
- Section: Articles
- URL: https://journals.eco-vector.com/2226-6976/article/view/275361
- ID: 275361
Cite item
Abstract
The epidemic of HIV infection remains a priority for the world community. Russia and Ukraine are a basic reservoir of this social infection, HIV being mainly transmitted through the parenteral route that is common among injection narcotic users. Highly active antiretroviral therapy is associated with side effects and HIV resistance. In these conditions, there is an increasing demand for second-line agents with a good safety profile and a high barrier to the development of resistance. Etravirine (ETR) (intelence®, Janssen-Cilag) and raltegravir (RAL) (isentress®, Merck Sharp & Dohme B.V.) are indicated as components of combination therapy for previously treated adult patients infected with HIV-1. Meta-analysis of the results of the DUET I, II (ETR) and BENCHMARK I, II (RAL) studies showed that these drugs had the same therapeutic effect. The purpose of this study was to make a pharmacoeconomic analysis of antiretroviral therapy with ETR and RAL in HIV-infected patients. This study used a cost-minimization analysis. The cost of the compared drugs was taken from the 2011 Federal tender prices within the priority National Health project. Comparison of the estimated number of patients treated with each drug indicated that the use of ETR can provide much more patients with equally effective therapy than that with RAL. The annual cost of ETR is vastly below that of RAL. This allows the choice of ETR to be used for the treatment of previously untreated HIV-infected patients.
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
Yu. B BELOUSOV
N.I. Pirogov Russian National Research Medical UniversityMoscow
E. V AFANASYEVA
OOO Center of Pharmacoeconomic StudiesMoscow
D. Yu BELOUSOV
OOO Center of Pharmacoeconomic Studies
Email: clinvest@mail.ru
Moscow
A. S BEKETOV
OOO Center of Pharmacoeconomic StudiesMoscow
References
- UNAIDS/WHO AIDS Epidemic Update, 2009.
- The antiretroviral therapy cohort collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin. Infect. Dis. 2010; 50: 1387-1396.
- The UK collaborative group on HIV drug resistance and UK CHIC study group. Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. Clin. Infect. Dis. 2010; 50 (9): 1275-1285.
- Аптека № 36 (807) 19 сентября 2011 г. http://www.apteka.ua/article/96397
- Eric S. Daar, Camlin Tierney et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV type-1, a randomized. Trial. Ann. Int. Med. 2011; 7: 154.
- Lazzarin A., Campbell T., Clotet B. et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370 (9581): 39-48.
- Madruga J.V., Cahn P., Grinsztejn B. et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370 (9581): 29-38.
- Efficacy of raltegravir, an HIV integrase inhibitor, in combination with regimens containing enfuvirtide, darunavir, or tipranavir in patients with triple-class resistant virus: combined results from BENCHMRK-1 and BENCHMRK-2. 11th European AIDS Conference, 2007.
- Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of raltegravir (MK-0518), a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 14th CROI Conference on retroviruses and opportunistic infections, 2007.
- Steigbigel R., Cooper D., Kumar P. et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med. 2008; 359 (4): 339-354.
- Hawkins N., Davies A. 30th Annual meeting of society for medical decision making. Philadelphia, USA. 18-22 October 2008. Abstract 30BMA.
- Отраслевой стандарт «Клинико-экономические исследования. Общие положения» 91500.14.0001-2002.
Supplementary files
![](/img/style/loading.gif)